Marcela Maus: Closing plenary to explore the future of CAR T-Cell therapy in solid tumors
Mediamedic posted on LinkedIn:
”Closing Plenary: The Future of CAR T-Cell Therapy in Solid Tumors
The final plenary of Tandem Meetings 2025, chaired by Dr. Marcela Maus (Massachusetts General Hospital Cancer Center, Harvard Medical School), explored the next frontier in cellular immunotherapy – expanding CAR T-cell therapy from hematologic cancers to solid tumors.
Speakers Dr. Saul Priceman (USC) and Dr. Julia Carnevale (UCSF) presented cutting-edge research on tumor microenvironment modulation, CRISPR-based functional genomics, and next-generation T-cell engineering aimed at overcoming T-cell exhaustion and antigen heterogeneity.
“This closing plenary offers an exciting glimpse into the future of cellular therapeutics,” said Dr. Maus. “We are united in improving the patient experience and curing disease by leveraging cells as medicine.” ”
Find more here.
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
-
Jan 12, 2026, 01:55Frank Weinz on State-of-the-Art Thromboembolism Prophylaxis